Dr. Parad is a Neonatologist in the Department of Pediatric Newborn Medicine (DPNM) at Brigham and Women's Hospital, Boston, and an Associate Professor in Pediatrics at Harvard Medical School. He underwent dual training in Perinatal-Neonatal Medicine and Pediatric Pulmonology at Boston Children's Hospital.  He is the Director of the DPNM's Program in Newborn Genomics. His research focuses on the use of genomic sequencing for screening and diagnosing disorders in the newborn period as well as clinical trials for improving the treatment of neonatal lung disorders. He was co-founder of the Massachusetts CF Newborn Screening Program, the first in the US to use a multivariant DNA panel as part of the screen, and was the first to identify CFTR Related Metabolic Syndrome (CRMS) as a byproduct of that screening algorithm. His CF expertise is in CF Newborn Screening, care of infants with CF and CRMS, and clinical implications of different CFTR variants.  He recently published guidelines for CF genetic counseling for support of families of newborns with a positive CF newborn screen and is supported by CFF to evaluate the development of a centralized telegenetic counseling service as a potential resource to families in regions where genetic counseling services are limited.